{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:20:03Z","timestamp":1788315603332,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.vaccine.2013.01.012","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T07:50:06Z","timestamp":1358927406000},"page":"1480-1489","source":"Crossref","is-referenced-by-count":28,"title":["A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen"],"prefix":"10.1016","volume":"31","author":[{"given":"William M.","family":"Gwinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun M.","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soman N.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman F.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2013.01.012_bib0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/clin.1997.4432","article-title":"Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases","volume":"85","author":"Xiao","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"issue":"17\/19","key":"10.1016\/j.vaccine.2013.01.012_bib0010","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","article-title":"Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants","volume":"19","author":"Pizza","year":"2001","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.01.012_bib0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.153.2.647","article-title":"Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin","volume":"153","author":"Snider","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.01.012_bib0020","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.4049\/jimmunol.165.9.4778","article-title":"Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues","volume":"165","author":"van Ginkel","year":"2000","journal-title":"J Immunol"},{"issue":"February (9)","key":"10.1016\/j.vaccine.2013.01.012_bib0025","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMp048006","article-title":"Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy","volume":"350","author":"Couch","year":"2004","journal-title":"N Engl J Med"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2013.01.012_bib0030","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1128\/IAI.69.4.2328-2338.2001","article-title":"(IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization","volume":"69","author":"Hodge","year":"2001","journal-title":"Infect Immun"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2013.01.012_bib0035","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.4049\/jimmunol.162.10.6141","article-title":"IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens","volume":"162","author":"Staats","year":"1999","journal-title":"J Immunol"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2013.01.012_bib0040","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JVI.76.2.517-524.2002","article-title":"Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization","volume":"76","author":"Bradney","year":"2002","journal-title":"J Virol"},{"issue":"February (9\/10)","key":"10.1016\/j.vaccine.2013.01.012_bib0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0264-410X(02)00737-5","article-title":"Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice","volume":"21","author":"Przetak","year":"2003","journal-title":"Vaccine"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2013.01.012_bib0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2003.12.011","article-title":"Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities","volume":"113","author":"Chisholm","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"December (52)","key":"10.1016\/j.vaccine.2013.01.012_bib0055","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1016\/j.vaccine.2008.09.045","article-title":"Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond","volume":"26","author":"Lahiri","year":"2008","journal-title":"Vaccine"},{"issue":"April (1)","key":"10.1016\/j.vaccine.2013.01.012_bib0060","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.4049\/jimmunol.1101764","article-title":"MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN Type I-independent mechanism of action","volume":"188","author":"Caproni","year":"2012","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2013.01.012_bib0240","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1086\/657087","article-title":"Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues","volume":"202","author":"El-Kamary","year":"2010","journal-title":"J Infect Dis"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2013.01.012_bib0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm1757","article-title":"Mast cell activators: a new class of highly effective vaccine adjuvants","volume":"14","author":"McLachlan","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.01.012_bib0075","doi-asserted-by":"crossref","first-page":"e19863","DOI":"10.1371\/journal.pone.0019863","article-title":"Intranasal immunization with recombinant HA and mast cell activator C48\/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice","volume":"6","author":"Meng","year":"2008","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2013.01.012_bib0080","doi-asserted-by":"crossref","first-page":"e16532","DOI":"10.1371\/journal.pone.0016532","article-title":"Mucosal targeting of a BoNT\/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT\/A neutralizing antibodies in rabbits","volume":"6","author":"Staats","year":"2011","journal-title":"PLoS ONE"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.01.012_bib0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jps.22742","article-title":"Stable dry powder formulation for nasal delivery of anthrax vaccine","volume":"101","author":"Wang","year":"2012","journal-title":"J Pharm Sci"},{"issue":"October (42)","key":"10.1016\/j.vaccine.2013.01.012_bib0090","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1016\/j.vaccine.2010.08.006","article-title":"Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1","volume":"28","author":"Gwinn","year":"2010","journal-title":"Vaccine"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2013.01.012_bib0095","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.4049\/jimmunol.172.9.5168","article-title":"Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice","volume":"172","author":"Rosset","year":"2004","journal-title":"J Immunol"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2013.01.012_bib0100","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.4049\/jimmunol.172.5.2739","article-title":"Cutting edge: activation of toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma","volume":"172","author":"Redecke","year":"2004","journal-title":"J Immunol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2013.01.012_bib0105","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1365-2222.2004.02023.x","article-title":"Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice","volume":"34","author":"Quarcoo","year":"2004","journal-title":"Clin Exp Aller"},{"issue":"April (13\/14)","key":"10.1016\/j.vaccine.2013.01.012_bib0110","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.vaccine.2004.01.037","article-title":"Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model","volume":"22","author":"Otero","year":"2004","journal-title":"Vaccine"},{"issue":"June (27)","key":"10.1016\/j.vaccine.2013.01.012_bib0115","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1016\/j.vaccine.2009.03.069","article-title":"The mast cell activator compound 48\/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen","volume":"27","author":"McGowen","year":"2009","journal-title":"Vaccine"},{"issue":"29\/30","key":"10.1016\/j.vaccine.2013.01.012_bib0120","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1016\/j.vaccine.2004.03.047","article-title":"Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins","volume":"September (22)","author":"de Jonge","year":"2004","journal-title":"Vaccine"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2013.01.012_bib0125","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.4049\/jimmunol.1100254","article-title":"Maximal adjuvant activity of nasally delivered IL-1alpha requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production","volume":"188","author":"Thompson","year":"2012","journal-title":"J Immunol"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2013.01.012_bib0130","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity","volume":"75","author":"Staats","year":"2007","journal-title":"Infect Immun"},{"issue":"November (9)","key":"10.1016\/j.vaccine.2013.01.012_bib0135","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J Immunol"},{"issue":"April (8)","key":"10.1016\/j.vaccine.2013.01.012_bib0140","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells","volume":"180","author":"Seubert","year":"2008","journal-title":"J Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2013.01.012_bib0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2567.2009.03164.x","article-title":"T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection","author":"Korsholm","year":"2010","journal-title":"Immunology"},{"issue":"December (10)","key":"10.1016\/j.vaccine.2013.01.012_bib0150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s004050000285","article-title":"Lipopolysaccharide-induced nasal cytokine response: a dose-response evaluation","volume":"257","author":"Danuser","year":"2000","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"June (11)","key":"10.1016\/j.vaccine.2013.01.012_bib0155","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.4049\/jimmunol.170.11.5636","article-title":"Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen","volume":"170","author":"Boyaka","year":"2003","journal-title":"J Immunol"},{"issue":"November (45)","key":"10.1016\/j.vaccine.2013.01.012_bib0160","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2013.01.012_bib0165","first-page":"48","article-title":"Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I","volume":"243","author":"Ghosh","year":"2006","journal-title":"Comparison with T cell receptor-induced responses. Cell Immunol"},{"issue":"August","key":"10.1016\/j.vaccine.2013.01.012_bib0170","first-page":"121","article-title":"Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery","volume":"354","author":"Wang","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"issue":"May\u2013June (3)","key":"10.1016\/j.vaccine.2013.01.012_bib0175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.3.3.4011","article-title":"Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge","volume":"3","author":"Huang","year":"2007","journal-title":"Hum Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2013.01.012_bib0180","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/IAI.60.7.2874-2879.1992","article-title":"Cholera toxin as a mucosal adjuvant: effects of H-2 major histocompatibility complex and lps genes","volume":"60","author":"Elson","year":"1992","journal-title":"Infect Immun"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2013.01.012_bib0185","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.0818-9641.2004.01285.x","article-title":"Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha\/beta","volume":"82","author":"Durand","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2013.01.012_bib0190","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00262-006-0262-3","article-title":"TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines","volume":"56","author":"Johnston","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"January (3\/4)","key":"10.1016\/j.vaccine.2013.01.012_bib0195","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"November (10)","key":"10.1016\/j.vaccine.2013.01.012_bib0200","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.4049\/jimmunol.155.10.4621","article-title":"Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4","volume":"155","author":"Marinaro","year":"1995","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2013.01.012_bib0205","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1073\/pnas.94.10.5267","article-title":"A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity","volume":"94","author":"Yamamoto","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Dec (6)","key":"10.1016\/j.vaccine.2013.01.012_bib0210","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0002-9440(10)61246-1","article-title":"Oral and nasal sensitization promote distinct immune responses and lung reactivity in a mouse model of peanut allergy","volume":"167","author":"Fischer","year":"2005","journal-title":"Am J Pathol"},{"issue":"August (37)","key":"10.1016\/j.vaccine.2013.01.012_bib0215","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax(R) (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2013.01.012_bib0220","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000211427","article-title":"The effect of topical steroid on the actions of vasoconstrictor and vasodilator peptides in human skin","volume":"9","author":"Goldsmith","year":"1996","journal-title":"Skin Pharmacol"},{"issue":"August (39)","key":"10.1016\/j.vaccine.2013.01.012_bib0225","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1016\/j.vaccine.2009.06.084","article-title":"Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans","volume":"27","author":"Couch","year":"2009","journal-title":"Vaccine"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2013.01.012_bib0235","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1398-9995.2009.02012.x","article-title":"Nasal CpG oligodeoxynucleotide administration induces a local inflammatory response in nonallergic individuals","volume":"64","author":"Mansson","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.vaccine.2013.01.012_bib0245","first-page":"590","author":"Virtala","year":"2012","journal-title":"Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin Exp Allergy Apr;42(4):"},{"key":"10.1016\/j.vaccine.2013.01.012_bib0250","first-page":"4844","author":"Morse","year":"2011","journal-title":"Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res Jul 15;17(14):"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T22:15:32Z","timestamp":1687990532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0264410X13000340"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.01.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}